Fujian Shengdi Pharmaceutical Co., Ltd.
Fujian Shengdi Pharmaceutical Co., Ltd.
Explore linked clinical trials.31 results ยท Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With Hypertriglyceridemia | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, metabolic disease | Recruiting | Phase 2 | 2026-10-09 | NCT07799688 | |
| A Study of HRS-4729 Injection in Participants With Type 2 Diabetes | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Not yet recruiting | Phase 2 | 2026-09-28 | NCT07843862 | |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 1 | 2026-09-28 | NCT07559136 | |
| A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1596 Tablets in Healthy Participants With a Single Dose and in Obese Participants With Multiple Doses | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Not yet recruiting | Phase 1 | 2026-09-25 | NCT07841860 | |
| A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of HRS-4139 in Healthy Participants | Psoriasis Vulgaris | Recruiting | Phase 1 | 2026-09-25 | NCT07802964 | |
| A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment | Body Weight, Digestive System Diseases, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, fatty liver disease, glucose metabolism disease, liver disorder, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus | Recruiting | Phase 1 | 2026-09-16 | NCT07807059 | |
| Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention | Fluid Retention Caused by Heart Failure | Recruiting | Phase 2 | 2026-09-16 | NCT07318103 | |
| A Mass Balance Study of [14C]HRS-9057 for Injection in Healthy Participants | Fluid Retention Due to Heart Failure | Active, not recruiting | Phase 1 | 2026-09-10 | NCT07681479 | |
| A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Recruiting | Phase 3 | 2026-09-08 | NCT07551492 | |
| Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis | Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis | Active, not recruiting | Phase 2 | 2026-09-08 | NCT07308392 | |
| A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting | Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, Digestive, Vomiting | Recruiting | Phase 2 | 2026-08-26 | NCT07709897 | |
| A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis | Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Recruiting | Phase 2 | 2026-08-26 | NCT07660848 | |
| A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects | Chronic Management of Body Weight | Recruiting | Phase 3 | 2026-08-13 | NCT07670884 | |
| Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension | Mild to Moderate Hypertension | Active, not recruiting | Phase 2 | 2026-07-31 | NCT07297797 | |
| Phase III Study of HRS-5635 in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B | Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B | Recruiting | Phase 3 | 2026-07-24 | NCT07606950 | |
| A Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes Mellitus | type 2 diabetes mellitus | Recruiting | Phase 2 | 2026-07-23 | NCT07599410 | |
| A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis | arthritic joint disease, arthropathy, musculoskeletal system disorder, osteoarthritis, osteoarthritis, knee, rheumatic disorder | Not yet recruiting | Phase 3 | 2026-07-17 | NCT07709910 | |
| A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Not yet recruiting | Phase 2 | 2026-07-08 | NCT07690826 | |
| HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke. | Acute Ischemic Stroke, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Active, not recruiting | Phase 2 | 2026-06-29 | NCT07233070 | |
| A Clinical Study to Evaluate the Effect of Different Dosing Conditions on the Pharmacokinetics of HRS9531 Tablets in Healthy Participants | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Not yet recruiting | Phase 1 | 2026-06-24 | NCT06506175 | |
| A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, metabolic disease | Active, not recruiting | Phase 2 | 2026-06-03 | NCT07100418 | |
| A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function | Body Weight, Body Weight Changes, Nutritional and Metabolic Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Weight Loss, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease | Recruiting | Phase 1 | 2026-06-01 | NCT07540754 | |
| A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events | Lipoprotein Disorder | Active, not recruiting | Phase 2 | 2026-03-05 | NCT07185776 | |
| A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 3 | 2026-02-27 | NCT07285902 | |
| A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy | Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy | Recruiting | Phase 3 | 2026-01-26 | NCT06994650 |